Tekla Life Sciences Investors
HQL · NYSE
3/31/2025 | 9/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $0 | $0 | $0 | $0 |
| Short-Term Investments | $12,161 | $0 | $0 | $15,242 |
| Receivables | $6,388 | $231 | $113 | $5,045 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | -$18,549 | $51 | $59 | -$15,242 |
| Total Curr. Assets | $0 | $282 | $172 | $5,045 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $460,301 | $429,950 | $397,529 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $13,901 | $11,826 | $0 |
| Total NC Assets | $0 | $474,203 | $441,776 | $397,529 |
| Other Assets | $411,342 | -$13,901 | $0 | $26 |
| Total Assets | $411,342 | $460,583 | $441,947 | $402,600 |
| Liabilities | – | – | – | – |
| Payables | $0 | $2 | $229 | $0 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $0 | $887 | $651 | $0 |
| Total Curr. Liab. | $0 | $889 | $880 | $0 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $887 | $651 | $667 |
| Total NC Liab. | $0 | $887 | $651 | $667 |
| Other Liabilities | $15,400 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $15,400 | $889 | $880 | $667 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $289 | $281 | $274 | $268 |
| Retained Earnings | -$30,516 | $44,128 | $30,193 | -$1,481 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $426,169 | $415,286 | $410,601 | $403,147 |
| Total Equity | $395,942 | $459,695 | $441,068 | $401,934 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $411,342 | $460,583 | $441,947 | $402,600 |
| Net Debt | $0 | $0 | $0 | -$0 |